Engineered immune cells take on Hard-to-Treat prostate cancer

NCT ID NCT05022849

Completed Disease control Sponsor: Janssen Research & Development, LLC Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-phase study tested a new treatment called JNJ-75229414, which uses a patient's own immune cells (T cells) engineered to attack prostate cancer cells. The study involved 15 men with metastatic castration-resistant prostate cancer that had already been treated with other therapies. The main goal was to find the safest dose and check for side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for METASTATIC CASTRATION-RESISTANT PROSTATE CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

castration-resistant prostate carcinoma metastatic prostate carcinoma prostate cancer prostate neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PROSTATIC NEOPLASMS

Contacts and locations

Locations

City of Hope Cancer Center

Duarte, California, 91010, United States
Columbia University Medical Center

New York, New York, 10032, United States
Icahn School of Medicine at Mount Sinai

New York, New York, 10029, United States
Levine Cancer Institute

Charlotte, North Carolina, 28204, United States
Norton Cancer Institute

Louisville, Kentucky, 40207, United States
University Of Minnesota

Minneapolis, Minnesota, 55455, United States
University of Pennsylvania

Philadelphia, Pennsylvania, 19104, United States
University of Utah Huntsman Cancer Institute

Salt Lake City, Utah, 84112, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.